Organon announced an agreement with Eli Lilly and Company to become the sole distributor and promoter for the migraine medicines Emgality® (galcanezumab) and RAYVOW™ (lasmiditan) in Europe.
Emgality, a humanized monoclonal antibody calcitonin gene-related peptide (CGRP) antagonist, is indicated for the prophylaxis of migraine in adults who have at least four migraine days per month. RAYVOW is a first-in-class serotonin 5-HT receptor agonist approved for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.
Migraine is the third most common disease worldwide causing recurrent moderate-to-severe headaches, often accompanied by other debilitating symptoms, including nausea, vomiting, and sensitivity to light and sound that can negatively interrupt an individual’s daily living including family life, career, education, relationships, and earnings. The disease is three times more common in women than in men and is one of the leading causes of disability in women.
Under the terms of the agreement, Organon will become the sole distributor and promoter of Emgality and RAYVOW in Europe. Lilly will remain the marketing authorization holder and will manufacture the products for sale.
Total consideration to be paid to Lilly includes an upfront payment of $50 million and sales-based milestone payments. The transaction is expected to close in Q1 2024 upon completion of review with relevant country-specific authorities.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!